AbbVie (ABBV) announced Tuesday that Health Canada has approved CONSTELLA (linaclotide) as a once-daily oral treatment for children and adolescents 6 to 17 years of age with functional constipation.
CONSTELLA is the first and only Health Canada-approved prescription therapy for functional constipation in this patient population.
Functional constipation is a chronic condition characterized by hard, infrequent bowel movements that are often difficult or painful to pass.
The approval of CONSTELLA is based on efficacy and safety results from a Phase 3 clinical trial, which met the primary endpoint evaluating linaclotide (72 mcg) for increased frequency of spontaneous bowel movements (SBM) in patients aged 6 to 17 years.
CONSTELLA is also indicated for the treatment of adults with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C).
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.